References to Primarv Literaturess
- WANG JC: DNA topoisomerases. Ann. Rev. Biochem.(1985) 54:665–697.
- GELLERT M: DNA topoisomerases. Ann. Rev. Biochem.(1981) 50:879–910.
- REECE RJ, MAXWELL A: DNA gyrase: structure and func-tion. Crit. Rev. Biochem. MoL Biol. (1991) 26(30-4):335–375.
- DRLICA K, FRANCO RJ: Inhibitors of DNA topoisom- erases. Biochemistry (1988) 27(7):2253–2259.
- LIU LF: DNA topoisomerase poisons as antitumour drugs. Ann. Rev. Biochem. (1989) 58:351–375.
- D'ARPA P, LIU LF: Topoisomerase-targeting antitumour drugs. Biochem. Biophys. Acta. (1989) 989:163–177.
- BRYSKIER A: Fluoroquinolones: mechanisms of action and resistance. Int.J. Antimicrob. Agents (1993) 2:151–184.
- SLICHENMYER WJ, ROWINSKY EK, DONEHOWER RC, KAUFMANN SH: The current status of captothedn ana-logues as antitumour agents. J. Natl. Cancer. Inst. (1993) 85(4): 271–291.
- HSIANG YH, HERTZBERG R, HECHT S, LIU LF:Carntothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase L J. Biol. Chem. (1985) 260:14873–14878.
- ANDREA JE, ADACHI K, MORGAN AR: Fluorome1ric as-says for DNA topoisomerases and topoisomerase-tar-geted drugs: quantitation of catalytic activity and DNA cleavage. Mol. Pharmacol. 1991, 40(4):495–501.
- YOSHIDA H, NAKAMURA M, BOGAKI M, ITO H, KOJIMA T, HATTORI H, NAICAO S: Mechanism of action of qui-nolones against Escbericbia coli DNA gyrase. Antimi-crob. Agents. Chemother. 1993, 37(4):839–845.
- ARAKI K, KURODA T, UEMORI S, MORIGUCHI A, IKEDA Y, HIRAYAMA F, YOKOYAMA Y, IWAO E, YAKUSHIJI: Qui-nolone antimicrobial agents substituted with mor-pholines at the 7-position: synthesis and structure-activity relationships. J. Med. Chem. (1993) 36:1356–1363.
- DOMAGALA JM, HAGEN SE, JOANNIDES T, KIELY JS, LABORDE E, SCHROEDER MC, SESNIE JA, SHAPIRO MA, SUTO KJ, VANDERROEST S: Quinolone antibacterials containing the new 7-[341-amilloelllY0- side chain: the effects of the 1-aminoethyl moiety and its stereochemical configurations on potency and in Vivo efficacy. J. Med.Chem. (1993) 36:871–882.
- LABORDE E, KIELY JS, CULBERTSON TP, LESHESKI LE: Quinolone antlbacterials: synthesis and biological ac-tivity of carbon isosteres of the 1-piperazinyl and 3-amino-l-pyrrolidinyl side chains. J. Med. Chem. (1993) 36:1964–1970.
- BARRETT JF, GOOTZ TD, MCGUIRK PR, FARRELL CA, SOKOLOWSKI SA: Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents. An-timicrob. Agents. Chemother. (1989) 33(10):1697–1703.
- ELSEA SH, OSHEROFF N, NMSS JL: Cytotoxicity of qui-nolones toward eukaryotic cells. Identification of topoi-somerase II as the primary cellular target for the quinolone CP-115,953 in yeast. J. Biol. Chem. (1992) 267(19):13150–13153.
- RAIBINSON MJ, MARTIN BA, GOOTZ TD, MCGUIRK PR, MOYNIHAN M, SUTCLLFFE JA, OSHEROFF N: Effects of quinolone derivatives on eukaryotic topoisomerase fl a novel mechanism for enhancement of enzyme-medi-ated DNA cleavage. J. Biol. Chem. (1991) 266(22):14585–14592.
- YOSHINORI Y, ASHIZAWA T, MORIMOTO M, HOSOMI J,NAKANO H: Antitamour quinolones with mammalian topoisomerase U mediated DNA cleavage activity. Can-cer Res. (1992) 52:2818–2822.
- KOHLBRENNER WE, WIDEBURG N, Nam'. D, SALDIVARA, CHU TW: Induction of calf thymus topoisomerase II-mediated DNA breakage by the antibacterial isothia-zoloquinolones A-65281 and A-65282. Antimicrob. Agents Chemother. (1992) 36(1):81–86.
- CORBETT AH, GUERRY P, PFLLEGER P, OSHEROFF N: Apyrimido[1,6,a] benziraidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential. Antimicrob. Agents Chemother. (1993) 37(12):2599–2605.
- FROELICH-AMMON SJ, MCGUIRK PR, GOOTZ TD, JEFSONMR, OSHEROFF N: Novel quinolones with activity against topolsomerase II: stereo specificity of the eulcaryotic enzyme. Antimicrob. Agents Chemother. (1993) 37(4):646–651.
- BAIR KW: Cancer drug development: current researchand patents 1992 - Part 1. Curr. Opin. Ther. Patents (1993) 3(6):695–742.
- TERADA T, FUJIMOTO K, NOMURA M, YAMASHITA J, WIERZBA K, YAMAZAKI R, SHIBATA J, SUGIMOTO Y, YAMADA Y: Antitumour agents: synthesis and biological activity of 413-alkyl derivatives containing hydroxy, amino, and amido groups of 4'-0-demethy1-4- desoxy-podophyllotoxin as antitumour agents. J. Med. Chem. (1993) 36:1689–1699.
- GONZALESPERDOMO M, DECASTRO SL, MEIRELLES MNSL,GOLDBERG S: Ttypanosonta cruzi proliferation and differentiation are blocked by topoisomerase-II inhibi-tors. Antimicrob. Agents Chemother. (1990) 34(9):1707–1714.
- CHAVALITSHEWIINKOON P, WILAIRAT P, GAMAGE S, DENNY W, FIGGITT D, RALPH R: Structure-activity rela-tionships and modes of action of 9-anilinoacridines against chloroquine resistant Plasmodium falcipartstn in vitro. Antimicrob. Agents Chemother. (1993) 37(3):403–406.
- HERTZBERG RP, JOHNSON RK: Antineoplastic agents.Ann. Reports Med. Chem. (1993) 28:167–175.
- ONO K, IICEGANI Y, NISHIZAWA M, ANDOH T: Menogaril,an anthracycline derivative, inhibits DNA topolsom-erase II by stabilizing cleavable complex. Jap. J. Cancer Res. (1992) 83(9):1018–1023.
- YAMASHITA Y, KAWADA SZ, NAKANO H: Induction ofmammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and oroboL Biochem. Pbarrn. (1990), 39(4):737–744.
- MCCULLOUGH JE, MULLER MT, HOWELLS AJ, MAXWELL A,O'SULLIVAN J, SUMMERILL RS, PARKER WE, WELLS JS, BONNER DP, FERNANDES PD: Clerocidin, a terpenoid antibiotic, inhibits bacterial DNA gyrase. J. Antibio. (Ja-pan) (1993) 46(3):526–530.
- YOSHINORI Y KAWADA S, FUNJII N, NAKANO H: Induc-tion of mammalian DNA topoisomerase I and II medi- ated DNA cleavage by saintopin, a new antitumour agent from fungus. Biochemistry (1991) 30:5838–5845.
- YAMASHITA Y, KAWADA SZ, FUZI N, NAKANO H: Induc-tion of mammalian DNA topoisomerase-II dependent DNA cleavage by antitumour antibiotic streptonigrin. Cancer Res. (1990) 50(18):5841–5844.
- TORNALETTI S, ANDERSEN AU, CHRISTIANSEN K, PFDRINIAM: 8- methoxycaffine inhibition of drosophila DNA topoisomerase IL Biochim Biophys Acta 1992, 1131(1):30–
- BASTOW ICF, BORT ID, FUKUSHIMA Y, ICASHIWADA Y, TANAKA T, NONAKA G, NISHIOKA I, LEE ICH: Inhibition of DNA topoisomerases by sanguiin 11-6, a cytotoxic dimeric ellagitannin from Sanguisorba Planta. Med. (1993) 59(3):240–245.
- KADOTA S, TAKAMORI Y, NYEIN KN, KIKUCHI T, TANAKA K, IKIMOTO H: Constituents of the leaves of Woodfordia fruticosa km-s. 1. Isolation, structure, and proton and carbon-13 nuclear magnetic resonance signal assign-ments of woodfruticosin (woodfordin C), an inhibitor of deoxyribonucleic acid topoisomerase II. Chem. Pharm. Bull. (Tokyo) (1990) 38(10):2687–2697.
- WALL ME, MANI MC, COOK CE: Plant antitumour agents. 1. The isolation and structure of camtothecin, a novel alkaloidal leukemia and tumour inhibitor from camp-totheca acuminata. J. Am. Chem. Soc. 1966, 88:3888–3890.
- KUNIMOTO T, NITTA K, TANAKA T, UEHARA N, BABA H, TAKEUCHI M, YOKOKURA T, SAWADA S, MIYASAKA T, MUTAI M: Antiturnour activity of 7-ethy1-1044-(1-piperidino)-1-piperdino]carbonyloxy- camptothecin, against murine tumours. Cancer Res. 1987, 47:5944–5947.
- KINGSBURY WD, BOEHM JC, JAICAS DR: Synthesis of water soluble (amino alkyl) camptothedn analogues: inhibition of topoisomerase I and antitumour activity. J. Med. Chem. 1991, 34:98–100.
- CHEN AY, YU C, BODLEY A, PENG LF, LIU LF: A newmammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 1993, 53:1332–1337.
- SUZUKI K, YAMAGUCHI H, MIYAZAKI S, NAGAI K: Topostin, a novel Inhibitor of mammalian DNA topoi-somerase I from flextbacter topostinus sp Nov. 1. taxonomy, and fermentation of producing strain. J. Antibio. (1990) 43(2):154–157.
- CHEN AY, YU C, GATTO B, LIU LF: DNA Minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. Proc. Natl. Acad. Sci. USA (1993) 90(17):8131–8135.
- CHAICRABORTY AK, MAJUMDER HK: Mode of action of pentavalent antimoniaLs: specific inhibition of type I DNA topoisomerase of Leisbnsana donovani. Biochem Biophys Res Commun (1988) 152(2):605–611.
- FANG S-D, WANG L-K, HECHT SM: Inhibitors of DNA topoisomerase I isolated from the Roots of Zantboxy-lum tdtidum. J. Org. Chem. (1993) 58(19):5025–5027.
- LI CJ, AVERBOUK L, PARDEE AB: Beta-lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J. Biol. Chem. (1993) 268(30):22463–22468.
- SORENSEN BS, SINDING J, ANDERSEN AIL ALSNER J, JENSEN PB, WESTERGAARD 0: Mode of action of topol-somerase II-targeting agents at a specific DNA sequence.
- GEWIRTZ DA, ORR MS, FORNARY FA, RANDOLPH JK, YALOWICH JC, RITKE MK, POVIRK LF, BUNCH RT: Disso-ciation between bulk damage to DNA and the antipro-lfferative action of teniposide (VM-26) ht. the MCF-7 breast tumour cell line: evidence for induction of gene specific damage and alterations in gene expression. Cancer Res. (1993), 53: 3547–3554.
- HOPPER DC: Quitkolone mode of action: new aspects. Drugs 1993, 45\(suppl 3):8–14.
- WILLMOTT CJR, MAXWELL A: A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antirni-crob. Agents. Chemother. (1993), 37(1):126–127.
- CAMPAIN JA, PADMANABHAN R, HWANG J, GOTTESMAN MM, PASTAN I: Characterization of an unusual mutant of human melanoma cells resistance to drugs that Inhibit topoisomerase II. J. Cell. Physiol. (1993), 155(2):414–425.
- WASSERMAN RA, AUSTIN CA, FISHER LM, WANG JC: Useof yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombi-nant human DNA topoisomerase Ha in yeast. CancerRes. (1993), 53:3591–3596.
- SHIMADA Y, YOSHINO M, WAKUI A, NAKAO I, FUTATSUKIK, SAKATA Y, KAMBE M, TAGUCHI T, OGAWA N: Phase 11 study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J. Clin. Oncol. (1993), 11(5):909–913.
- THOMPSON DS, HAINSWORTH JD, HANDE KR, HOLZMERMC, GRECO AI Prolonged administration of low dose, infusional etoposide in patients with etoposkle sensi-tive neoplasms: a Phase I/11 study.]. Clin. Oncol. (1993), 119(7):1322–1428.
- PEIN F, PINKERTON R, TOURADE ME, BRUNAT-MENTIGNY M, LEVITT G, MARGUERIFIE G, RUBLE H, SOMMELET D, THYSS A, ZUCKER JM: Etoposide in relapsed or refrac-tory wilm's tumour: a phase II study by the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J. Clin. Oncol. 1993, 11(8):1478–1481.
- PODDEVIN B, RIOU JF, LAVELLE F, POMMIER Y: Dualtopoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumour agent in early clinical trials. Mol. Pharmacol. (1993) 44(4): 767–774.
- LARSEN AK, GRONDARD L, COUPRIE J, DESOIZE B, CO-MOE L, JARDILLIER JC, RIOU JF: The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisimerase I and Biochem. Pharmacol. (1993) 46(8): 1403–1412.
- LORICO A, LONG BH: Biochemical characterisation of elsamicin and other cournarin related antitumor agents as potent inhibiors of human topoisomerse IL Eur. J. Cancer (1993) 29A(14): 1985–1991.
- MANUEL J, DENNY W, GAMAGE S, RANSIJN A, WOJCIK S, FIGGITT D, RALPH R: 9-Anilinacridines as potential antileishmanial agents. Antimicrob. Agents. Chemother. 1993, 37(5):991–996.
- FIGGITT D, DENNY W, CHAVALITSHEWINKOON P, WILAI-RAT P, RALPH R: In Vitro Study of Anticancer Acridines as Potential Antitrypanosomal and AntitnalarialAgents. Antimicrob. Agents Chemother. 1992, 36(8)1644–1647.
- RIOU G, DOUC-RASY S, KAYSER A: Inhibitors of trypano-some topoisomerases. Biochem. Soc. Trans. (1986), 14:496–499.
- SHAPIRO TA: Inhibition of topoisomerases in African trypanosomes. Acta Trop. (Basel) (1993), 54:251–260.
- CHAKRABORTY AK, MAJUMDER HK: Decatenation of kinetoplast DNA by an ATP-dependent DNA topoisom-erase from the kinetoplast hemoflagellate Leishmania donovani. Mol. Biochem. Parasitol. 1987, 26:215–224.
- SHAPIRO TA, ENGLUND PT: Selective cleavage of kineto-plast DNA minicircles promoted by antbrypanosomal drugs. Proc. Natl. Acad. Sci. USA (1990) 87:950–954.
- BELL CA, Dykstra CC, Naiman NA, Cory M, Fairly TA, Tidwell RR: Structure-activity studies of dicationically substi-tuted bisbenzimidazoles against Giardia lambita: cor-relation of antigiardial activity with DNA binding affinity and giardial topoisomerase II inhibition. An-timicrob. Agents Chemother. (1993) 37(12):2668–2673.
- BASSINI C, BISMARA C, CARLESS° R, FERIANI A, GAVI-RAGHI G, MARCHIORO C, PERBONI A, SHAW RE, TAM-BURINI B, TARZIA G: Synthesis and antimicrobial activity of DNA-gyrase inhibiting derivative of 4-oxo-1,4,dihydro-3-pyridinecarboxylic add. Farmaco. (1993), 48(2):159–189. YOSHIDA T, MITSUHASHI S: Antibacterial activity of NM394, the active form of prodrug NM441. Antimicrob. Agents Chemother. (1993), 37(4):793–800. MUKHARJEE A, SEN S, AGARWAL K: Ciprofloxacln, mam-malian DNA topoisomerase type II poison In Vivo. Mutat. Res. (1992), 301(2):87–92. SCHRODER HC, MERZ H, STEFFt,N R, MULLER WE, SARIN PS, TRUMN S, SCHULZ J, EICH E: Differential in vitro anti HIV activity of natural ligroin. Z. Naturforsch. (1990), 45(11–12):1215-1221.
References to patent literature
- BARTON et al., UK830832 (1960).
- WARNER-LAMBERT CO, EP-200307-B (1989).
- WARNER-LAMBERT CO, EP-342641-A (1989).
- WARNER-LAMBERT CO, US4916229 (1990).
- WARNER-LAMBERT CO, US5047538 (1991).
- WARNER-LAMBERT CO, US4945160 (1990).
- BAYER AG, EP-235676-B (1990).
- BAYER AG, EP-350733-A (1990).
- BAYER AG, U54840954 (1989).
- BAYER AG, U54841059 (1989).
- BAYER AG, US4847375 (1989).
- PFIZER INC, U54861779 (1989).
- PFIZER INC, 'W09002123 (1990).
- PFIZER INC, EP-413455-A (1991).
- ABBOTT LABORATORIES, U55057520 (1991).
- ABBOTT LABORATORIES, EP-360258-A (1990).
- AMERICAN CYANAMIDE CO, EP-439668-A (1991).
- AMERICAN CYANAMIDE CO, US4948894-A (1990).
- IMPERIAL CANCER RES TECH LTD, W09319037 (1993).
- GILLIGAN et al., US4623650 (1986).
- SYNPHAR LAB INC, W09210492 (1992).
- F HOFFMAN La ROCHE AG, W09218490 (1992).
- UNIVERSITY OF NORTH CAROLINA, W09322319 (1993).
- ICI PLC, EP-471516-A (1992).
- KYORIN PHARMACEUTICAL LTD, EP–471358–A.
- SMITHKLINE BEECHAM LTD, W09205785 (1992).
- TAKEDA CHEM IND LTD, EP-556585-A (1993).
- SMITHKLINE BEECHAM CORP, US5004758.
- SMITHKLINE BEECHAM CORP, W09311770 (1993).
- SMITHKLINE BEECHAM CORP, W09214471 (1992).
- SMITHKLINE BEECHAM CORP, W09214470 (1992).
- SMITHKLINE BEECHAM CORP, W09214469 (1992).
- SMITHKLINE BEECHAMNE BEECHAM CORP, W09309782 (1993).
- GLAXO INC, EP-540099-A (1993).
- GLAXO INC, W09221661 (1992).
- GLAXO INC, EP-496634-A (1992).
- JOHNSON & JOHNSON RES PTY LTD, W09210198 (1992).
- BORON BIOLOGICAL INC, W09309123 (1993).
- ADIR ET CO, EP-591058-A (1994).
- UNIVERSITE LIBRE DE BRUXELLES, W09403616 (1994).
- BAYER AG, US4952695 (1990).
- WAKUNA SEIYAKU ICC, EP-393400-A (1990).
- MAGAININ SCIENCES INC, W09200090 (1992).
- YALE UNIVERSITY, W09109616 (1991).
- DANA FARBER CANCER INST, W09220813 (1992).
- SMITH KLINE BEECHAM LTD, W09207856 (1992).
- UNIVERSITY OF ILLINOIS, W09207071 (1992).
- BAYER AG, EP-422485-A (1989).
- LAB ROGER BELLON, EP-431991-A (1991). AK Chakraborty5, Center for Molecular and Structural Biology, Hollings Cancer Center, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425–2213, USA, from 01 July 1994.